Director, Clinical Biomarker Development bei Revolution Medicines

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers.  The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

This role will be the Translational Medicine clinical biomarker development lead for 1-2 specific programs/molecules, which includes the strategic vision, clinical design and implementation of translational plans. Activities will be centered around systematic collection and robust analysis of clinical biomarker data and will have impact on drug development from IND to NDA.

As Director of Clinical Biomarker Development in Translational Medicine, you will:

• Develop and maintain translational and clinical biomarker strategies to support portfolio assets from phase 1 to phase 3 studies.

• Lead or participate in cross-functional teams such as program core teams, clinical working groups, and clinical study execution teams.

• Work with internal translational groups, contract research organizations and collaborators to develop and validate assays for clinical use.

• Support the development of biomarker related aspects of the trial design, including assay development, patient sample acquisition, study protocols, clinical biomarker plans, and other regulatory documents.

• Manage outsourcing to CROs, oversee development of the scope of work, contracting, budgets, and timelines.

• Collaborate with Clinical Bioinformatics and Cancer Genomics to support analysis of biomarker readouts, presenting outputs to internal and external stakeholders.

• Partner with an advisory network, form connections with KOLs and the biomarker community.

Required Skills, Experience and Education:

• Ph.D in cancer biology, cell/molecular biology, genomics or equivalent is required.

• 5+ years of clinical biomarker and/or assay development experience in industry is required.

• Experience and track-record of the development, validation, and clinical implementation of biomarker readouts is required.

• Experience of working with Contract Research Organizations to develop assays and deliver biomarker readouts is required.

• Excellent scientific and business communication skills, strong interpersonal/collaboration skills and planning skills.

• Ability to think critically and creatively and be able to work independently to determine appropriate resources for resolution of problems.

• Ability to multi-task and thrive in a fast-paced innovative environment.

Preferred Skills:

• Scientific knowledge of RAS-MAPK biology is preferred.

• Expertise using analytical sotware and/or genomic analysis packages.

• Biological understanding of pancreatic, non small cell lung and/or colorectal cancers is preferred. #LI-Hybrid  #LI-SH1